Top Banner
Children’s Minnesota Pharmacogenomics Implementation David Gregornik, BA, BS, Pharm.D. BCOP Pharmacogenomics Program Director
23

Children’s Minnesota Pharmacogenomics

Jun 15, 2022

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Children’s Minnesota Pharmacogenomics

Children’s Minnesota Pharmacogenomics

Implementation

David Gregornik, BA, BS, Pharm.D. BCOP

Pharmacogenomics Program Director

Page 2: Children’s Minnesota Pharmacogenomics

2 | © 2016

One of the largest freestanding pediatric health systems in the

United States

Children’s Minnesota

Minneapolis St Paul

429 Staffed beds

5,230 Employees

Page 3: Children’s Minnesota Pharmacogenomics

3 | © 2016

• 12 Primary care clinics

• 2 Emergency Departments

• 9 Specialty care sites

• 6 Rehabilitation sites

Children’s Minnesota

Page 4: Children’s Minnesota Pharmacogenomics

4 | © 2016

Page 5: Children’s Minnesota Pharmacogenomics

5 | © 2016

• Membership

− Pharmacist, Chair

− Genetics/genomics

− Hematology/oncology

− Behavioral health

− Anesthesiology

− Pathology

− Clinical informatics

− CMIO

− Administration/strategy

− Ad hoc – Antimicrobial Stewardship, Pain and Palliative Care, Developmental Pediatrics

Pharmacogenomics Oversight Committee (POC)

Page 6: Children’s Minnesota Pharmacogenomics

6 | © 2016

• Clinic opened 2/10/2017

• Pharmacist and genetic counselor

• Referred by primary care, behavioral health, and

developmental pediatrics services

• Appointment types:

− Pre-test evaluation appointment

Prior authorization obtained before PGx testing ordered

− Results review appointment

• 2 – 3 patients 1 day per week

• 1 – 2 inpatient consults per month

Pharmacogenomics Clinic

Page 7: Children’s Minnesota Pharmacogenomics

7 | © 2016

Children’s Minnesota EHR Implementation

• PGx result entry

• PGx result display

• Electronic clinical decision support

Page 8: Children’s Minnesota Pharmacogenomics

8 | © 2016

PGx Result Entry in EHR – Cerner PowerForm

• Results received in PDF format from all PGx labs

−Requires result entry by hand

• PowerForm Functionality

−Entry of discrete PGx results

−Automatically builds interpretive consults

−Allows for customized interpretive consults

• Standard consult text exists in a table outside of the results

page.

−Allows for updating interpretive consult without updating each

result individually.

Page 9: Children’s Minnesota Pharmacogenomics

9 | © 2016

PGx Result Entry in EHR – Cerner PowerForm

Page 10: Children’s Minnesota Pharmacogenomics

10 | © 2016

PGx Result Entry in EHR – Cerner PowerForm

Page 11: Children’s Minnesota Pharmacogenomics

11 | © 2016

PGx Result Entry in EHR – Cerner PowerForm

Page 12: Children’s Minnesota Pharmacogenomics

12 | © 2016

Pharmacogenomic Results Page (Cerner M-page)

Page 13: Children’s Minnesota Pharmacogenomics

13 | © 2016

Pharmacogenomic Results Page (Cerner M-page)

Gene/Drug Interactions

highlighted in RED

Page 14: Children’s Minnesota Pharmacogenomics

14 | © 2016

Interpretive Consult for Individual Results

Standard Consult Format:

•Diplotype

•Phenotype

•Dosing Recommendation

Page 15: Children’s Minnesota Pharmacogenomics

15 | © 2016

Individualized Medication Recommendations

Additional Resources

& Contact Information

Medications with evidence

based gene/drug interactions

Page 16: Children’s Minnesota Pharmacogenomics

16 | © 2016

Point of Care Alerts for High Risk Gene/Drug

Interactions

Page 17: Children’s Minnesota Pharmacogenomics

17 | © 2016

Point of Care Alert – 2 Gene Results

Page 18: Children’s Minnesota Pharmacogenomics

18 | © 2016

• Implementations to date

− TPMT: Thioguanine, 6-mercaptopurine & Azathioprine

− CYP2C19: Voriconazole, Citalopram, Escitalopram

− CYP2D6: Ondansetron, Tramadol, Aripiprazole, Nortriptyline,

Desipramine

− CYP2C19 & CYP2D6: Amitriptyline, Imipramine, Doxepin

Pharmacogenomics at Children’s Minnesota

Page 19: Children’s Minnesota Pharmacogenomics

19 | © 2016

Children’s Minnesota Data

• Genes implemented in

EHR:

−TPMT

−CYP2C19

−CYP2D6

As of December 31, 2017

• N = 394 patients

• 839 discrete results

46%

54%

Patients with Actionable Results

Normal Results

Actionable Results

Page 20: Children’s Minnesota Pharmacogenomics

20 | © 2016

• Strong administration commitment

• Multidisciplinary oversight committee

• Dedicated pharmacist leading implementation

• Enthusiastic pharmacy service

• Customizable (Cerner) EHR

• Experienced IT analyst

• PGx laboratory with > 10 years of experience

• CPIC Guidelines

Success Factors

Page 21: Children’s Minnesota Pharmacogenomics

21 | © 2016

• Reimbursement for testing and professional services

• Educating professional staff

• Educating patients

• EHR interoperability – Cerner vs. eClinical Works

Ongoing Challenges

Page 22: Children’s Minnesota Pharmacogenomics

22 | © 2016

Thank You!

Pharmacogenomics Oversight Committee

• Bruce Bostrom

• David Dassenko

• Paul Jensen

• Jen Miller

• Kim Oberstar

• Robyn Reed

• Ann Samuelson

• Gunter Scharer

• Susan Sencer

• Rabindra Tambyraja

• Mike Troy

• Colleen Wherley

• Cathy Wright

Expert Resources

• Stefan Friedrichsdorf

• Steve Grapentine

• Bill Pomputius

• Ulrich Broeckel

• Mark Dunnenberger

• Cyrine Haidar

• James Hoffman

Administration/Strategy/Informatics

• Laura Madsen

• Mary Ellen Mattson

• Nancy Mendelsohn

• Trevor Sawallish

• Judy Wenzel

• Carol Wilcox

• Greg Zarambo

Page 23: Children’s Minnesota Pharmacogenomics

23 | © 2016

Questions?